A concise synthesis of AMN107, a compound currently undergoing several phase II/III
clinical trials for chronic myelogenous leukemia is described. The new procedure reduces
the number of synthetic steps from eight to four, with an overall yield of 65%.
AMN107 - Abl kinase inhibitor - Cu-catalyzed N-arylation - Pd-catalyzed N-arylation
- atom economy